As the medical community continues to refine strategies for prostate cancer (PCa) detection, recent clinical research has reaffirmed the critical role of serum biomarkers, particularly free prostate-specific antigen (f-PSA), in improving diagnostic accuracy and reducing unnecessary procedures.
A significant study published in Scientific Reports highlights how PSA derivatives can help minimize the overutilization of magnetic resonance imaging (MRI) in men with a history of negative prostate biopsies . The research underscores that the ratio of free-to-total PSA (%fPSA) is a powerful tool for risk stratification. By establishing an optimal cutoff value of 18.76% for %fPSA, the study suggests that restricting MRIs to patients meeting specific biomarker criteria could reduce imaging rates by 22.7% while missing only 9.1% of clinically significant PCa cases . This approach not only alleviates the financial burden on healthcare systems but also spares patients from unnecessary investigations.
In alignment with these advancements in diagnostic precision, Xiamen Baysen Medical is committed to enhancing the accuracy of prostate cancer management through high-quality in vitro diagnostics. We work with Abbott since 2017.We are confident with our product quality.
This newly registered quality control product is specifically designed for use with electrochemiluminescence assays to monitor critical parameters, including total PSA (tPSA) and free PSA (fPSA) , alongside other tumor markers like AFP and Ferritin . By ensuring the precision and reliability of f-PSA testing, this control product enables laboratories to provide clinicians with trustworthy %fPSA ratios, facilitating better-informed decisions on patient management.
With this addition, Xiamen Baysen Medical have PSA and f-PSA Rapid test kit for early diagnosis. This further solidifies the company’s portfolio in the immunodiagnostics field, reinforcing its dedication to providing comprehensive solutions that meet the evolving demands of precision oncology. As research continues to validate the utility of biomarkers like f-PSA in refining diagnostic pathways, [Your Company Name] remains at the forefront, supplying the essential tools for quality assurance and clinical confidence.
Post time: Mar-13-2026